Bedrijf laden
Just reported
Q3 2026 results
From Hims & Hers Health's results release of 9 november 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 890,4M
+49% y/y
+18% q/qGuided
US$ 890M
midpoint
Within guide0,0%EPS, GAAP
Actual
US$ -0,14
Guided
—
No guide given
Operating income, GAAP
Actual
US$ -66,1M
Guided
—
No guide given
Company outlook
Q4 2026
- RevenueUS$ 875M – US$ 895M+43% y/y First given
Full year 2026
- RevenueUS$ 3,13B – US$ 3,15B+34% y/y Lowered -1,9%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Hims & Hers Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company LimitedUS$ 33,5BA
NBIXNeurocrine Biosciences, Inc.US$ 17,6BA+
ELANElanco Animal Health IncorporatedUS$ 13,2BA
KNSAKiniksa Pharmaceuticals International, plcUS$ 8,1BA+
LQDALiquidia CorporationUS$ 5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 okt 2026BAGraded B, now A
Hoe het geld verdient
- Sales to customers in the United States87%
- Sales to customers outside the United States13%
De omzetaandelen zijn schattingen voor quarter ended March 31, 2026, geen cijfers uit een ingediend rapport.
Concurreert met
Wat het verkoopt5
Prescription treatments
Medicines prescribed by clinicians for conditions including sexual health, hair loss, hormone health, weight loss, skin conditions, and mental health. Prescriptions may be filled by company-owned or partner pharmacies.
Weight-loss care and medicines
Weight-loss medicines, including access to branded medicines and, on a limited scale, compounded medicines, with a membership that can include ongoing clinician support.
Non-prescription products
Products such as skin care, hair care, sexual wellness products, cosmetics, and supplements, sold under Hims & Hers or co-branded with manufacturers.
Nog 2 tonen
Laboratory testing
Testing services that measure health markers and provide results to support health assessments and follow-up care with clinicians.
Telehealth consultations and follow-up care
Remote consultations with licensed healthcare professionals, who assess customers and may prescribe medication or provide ongoing care.
Wie het koopt3
- Consumers who buy prescription treatments and related care directly through Hims & Hers websites and apps; many choose recurring subscriptions and are billed when products ship or services are provided.
- Consumers who make one-time purchases through the websites, apps, or retail stores.
- Retail partners that buy or sell Hims & Hers non-prescription products in stores and on third-party websites.
Waar het op steunt, en wat het kan breken
Waar het bedrijf van afhangt
- 1In the United States, clinical care depends on contractual relationships with independent affiliated medical groups, which retain control over medical decisions.
- 2Fulfilling prescriptions depends on licensed company-owned and partner pharmacies, product manufacturers, and suppliers.
- 3The business depends on access to the internet, cloud and payment providers, and systems that handle sensitive customer health information.
- 4Selling and fulfilling medicines, compounded drugs, and laboratory tests depends on healthcare, pharmacy, product-safety, and privacy rules in each market.
Wat er mis kan gaan
- 1Regulators may restrict compounded medicines, including weight-loss drugs. The company received warning letters concerning promotion of compounded products, and the United States Food and Drug Administration said it intended to restrict certain ingredients for mass-marketed compounded drugs.
- 2Changes in telehealth and medical-practice rules could disrupt the company’s arrangements with affiliated medical groups or limit how clinicians assess patients and prescribe medicines.
- 3A data breach or failure to comply with changing privacy laws could expose sensitive health information, trigger penalties or lawsuits, and damage customer trust.
Over Hims & Hers Health, Inc.
Customers use Hims & Hers websites and apps to find treatments, answer health questions, and connect with licensed healthcare professionals. When appropriate, clinicians prescribe medication, which Hims & Hers or other licensed pharmacies ship to customers; customers can also buy non-prescription products and laboratory testing. In the United States, independent medical groups make clinical decisions, while Hims & Hers provides administrative and technology services. It had 2.891 million subscribers (June 30, 2026, high), meaning customers with recurring billing; monthly revenue per average subscriber was $92 (three months ended June 30, 2026, high), a measure that also includes revenue from one-time purchases.
- Hoofdkantoor
- San Francisco, California
- Opgericht in
- 2017
- Medewerkers
- 2,442 (December 31, 2025, high)
- Genoteerd aan
- NYSE
- Einde boekjaar
- December 31
Gebouwd uit de eigen deponeringen van Hims & Hers Health, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
